摘要
缺血性心脏病已成为世界上第一大致死性疾病,冠心病就是最常见的一种缺血性心脏病。冠心病的病理机制尚未被完全阐明,近年来研究发现肠道微生物与冠心病的发生发展密切相关。肠道微生物的中间代谢产物氧化三甲胺(TMAO),短链脂肪酸(SCFAs),胆汁酸(BAs),脂多糖(LPS)与冠心病的进展及预后存在确切相关性,调控肠道菌群可以起到干预冠心病及其危险因素的作用。目前的干预策略主要包括补充益生菌调整菌群结构、减少TMAO产生,增加SCFAs 3种途径,能达到稳定斑块,控制血压、血脂、血糖,减轻肥胖的效果。传统中药具有多成分、多靶点的治疗优势,其防治冠心病的作用也应囊括这3方面的机制。该文总结国内外关于中药单体及复方针对肠道菌群干预冠心病的研究,探索肠道菌群与冠心病发生发展的关系,梳理出3种主流的干预策略;其次综述中药单体与中药复方对冠心病、高血压、血脂异常、血糖异常及肥胖的研究进展,以期为中医药治疗心血管疾病提供更多的理论依据,并为今后该领域的研究提供一定的指导意义。
Ischemic heart disease has became the world′s most common deadly disease,and coronary heart disease(CHD)is the most common type of ischemic heart disease.The pathological mechanism of CHD has not been fully elucidated.In recent years,scientific studies have found that gut micro-biota are closely related to the occurrence and development of CHD,and CHD could be intervened by regulating gut micro-biota because of the correlation between CHD and intermediate metabolite of gut micro-biota.Current intervention strategies mainly include probiotics supplementation,reduction of TMAO and increase of SCFAs,which can achieve the effect of stabilizing plaques,and controlling blood pressure,blood lipids,blood glucose and obesity.Traditional Chinese medicine(TCM)has the multi-component and multi-target effects,which is correlated to its role in the prevention and treatment of CHD.This paper summarizes the domestic and foreign researches on the effect of TCM in attenuating CHD and its main risk factors by regulating gut micro-biota.The article aims to explore the correlation between gut micro-biota and CHD,and propose three main intervention strategies.Furthermore,the research progress of TCM on CHD,hypertension,dyslipidemia,hyperglycemia and obesity is reviewed by the categories of Chinese medicine monomer and compound,in the hope to provide more theoretical basis for TCM therapy on CHD and guidance for further studies in this field.
作者
杨光
何浩强
陈光
王阶
YANG Guang;HE Hao-qiang;CHEN Guang;WANG Jie(Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第1期29-36,共8页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81673847)
中央级公益性科研院所基本科研业务费专项(Z210-013).
关键词
中医药
肠道菌群
冠心病
危险因素
治疗
traditional Chinese medicine
gut micro-biota
coronary heart disease
risk factors
therapy
作者简介
杨光,硕士研究生,E-mail:gabrielyg@163.com;通信作者:王阶,博士,主任医师,教授,Tel:(010)88001018,E-mail:wangjie0103@126.com
